The influence of metoprolol in patients with sepsis-induced cardiomyopathy: A retrospective study

Saudi Med J. 2023 Oct;44(10):1030-1036. doi: 10.15537/smj.2023.44.10.20230149.

Abstract

Objectives: To focus on evaluating the clinical influence of metoprolol on sepsis-induced cardiomyopathy (SICM).

Methods: A total of 90 patients with SICM was enrolled from December 2018 to February 2021 and divided into 2 groups according to the use of metoprolol during hospitalization in Suzhou Municipal Hospital in Suzhou, China. We compared them with the cardiac function, sequential organ failure assessment score, and clinical outcomes.

Results: Between the 2 groups, the oxygenation indices and Glasgow coma scale in the metoprolol group were higher on the first day of treatment, with Glasgow coma scale higher on the third day of treatment. However, the doses of norepinephrine in patients with metoprolol showed no significant differences with the control group. The all-causemortality at 28 days in the metoprolol group was lower, and the time of removing from ventilator support as well as the number of failured organs also significantly differed between the 2 groups.

Conclusion: Metoprolol can reduce the 28-day mortality and shorten the duration of mechanical ventilation in SICM. It can also reduce the number of organ failures and improve the oxygenation index and Glasgow coma scale of these patients. Meanwhile, metoprolol did not affect the norepinephrine dose in patients with SICM.

Keywords: 28-day mortality; metoprolol; organ function; sepsis-induced cardiomyopathy.

MeSH terms

  • Cardiomyopathies* / drug therapy
  • Cardiomyopathies* / etiology
  • Humans
  • Metoprolol / therapeutic use
  • Norepinephrine / therapeutic use
  • Retrospective Studies
  • Sepsis* / complications
  • Sepsis* / drug therapy

Substances

  • Metoprolol
  • Norepinephrine